The Priority Review

Tag

Small Cell Lung Cancer

1 story

  1. Clinical trials

    Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer

    Merck Sharp & Dohme LLC has registered a Phase 3 randomized study to evaluate the safety and efficacy of Gocatamig (MK-6070) with Durvalumab versus Durvalumab alone as consolidation therapy in limited-stage small cell lung cancer. The trial plans to enroll 564 participants and is expected to start on December 7, 2026.